IFNA2 and myelofibrosis: Another study looked retrospectively at patients with primary or secondary myelofibrosis who received at least 6 months of Peg-IFN-α-2a treatment, and found that 82% of patients had resolution of their constitutional symptoms, 38.5% achieved transfusion independence, and 82.8% achieved complete resolution of their thrombocytosis [63].